Aquestive Therapeutics, Inc.
Income Statement
| Line Item | FY2017 |
|---|---|
| Revenue | $66.9M |
| Cost of Revenue | — |
| Gross Profit | — |
| Gross Margin | — |
| Operating Expenses | |
| Research & Development | $22.1M |
| SG&A Expense | $25.1M |
| Operating Income | $-113.0K |
| Operating Margin | -0.2% |
| Interest Expense | $7.7M |
| Pretax Income | $-8.9M |
| Income Tax Expense | $0 |
| Net Income | $-8.9M |
| Net Margin | -13.4% |
| EPS (Basic) | — |
| EPS (Diluted) | — |
| Shares Outstanding (Basic) | — |
| Shares Outstanding (Diluted) | — |
| Dividends Per Share | — |